Wockhardt

YEAR                                                     EVENTS
 
 2000 - Wockhardt has launched cardiac drug enalapril maleate in the
 US through its 
              marketing joint venture with Sidmak Laboratories.
 
           - Pharmaceutical major Wockhardt Ltd has set up a corporate
 training centre with
             modern and state-of-the-art facility under one roof at 
 Aurangabad.
 
 2001 - Wockhardt Hospitals Ltd, the wholly owned subsidiary of
 Wockhardt Ltd, will set up
               two cardiac hospitals in Mumbai and Bangalore.
 
           - The Company has terminated its three-year old marketing
 alliance with Sidmak 
              Laboratories, one of the top ten generic pharma
 companies in the US.
 
           - Pharma major Wockhardt Ltd. has entered into a strategic
 alliance with a Japanese
              firm Eisai Company Ltd. to manufacture and market a
 neurology drug -- Methycobal.
 
            - Wockhardt Hospitals Ltd, the wholly owned subsidiary of
 pharmaceutical major 
              Wockhardt Ltd, has tied up with four international
 health insurance companies to
             offer medical cover to non-resident Indians.
 
           -  AGM JUNE 8 2001 Wockhardt has launched an innovative and
 attractive employee stock option                            scheme, 
 ESOP.
 
           - Wockhardt Ltd has introduced an employee stock option
 (ESOP) scheme for over 175 employees
             in the senior and middle management levels with about
 2,00,000 shares being allotted.
   
 2002  
 
 -The Hari L Mundra has joined  Wockhardt as vice-chairman. Mundra
 will spearhead the              company's domestic operations which
 account for 70 per cent of its turnover.
 
 - Wockhardt Ltd has appointed Mr. Lalit Kumar as Executive Director
 on its Corporate             Board. Mr. Kumar will spearhead
 Wockhardt's International Business covering bulk drug            
 operations and formulations export, as well as ANDA research and
 Intellectual Property                          Rights.
 
 2003
 
 -Wockhardt restructured its field organization to upgrade its
 competitiveness and
 productivity.
 
 -Mumbai based wockhardt will hit the domestic market with the first
 indigenously 
 developed insulin soon, in a move to induce turmoil in the market.
 
 -Wockhardt has launched new four speciality hospitals at its Mulund
 complex in Mumbai.
 
 -Maharashtra Government decided to terminate its Joint Venture
 agreement with
 Wockhardt for setting up a super speciality hospital.
 
 -Wockhardt Limited has acquired CP pharmaceuticals(Holdings) Ltd,
 along with 
 its subsidiaries.
 
 -Wockhardt is strengthening its marketing strategies and distribution
 system to
 unveil human insulin in Indian market.
 
 -Wockhardt Launched Asia's first human recombinant insulin, making
 India the
 first Asian country to develop, manufacture and market the product.
 
 -Wockhardt Ltd has received USFDA approval for marketing bethanecol
 Chloride
 tablets in the US.
 
 -Wockhardt baged USFDA approval for Bethanechol
 
 -Baged US approval to sell bethanechol chloride tablets
 
 -Wockhardt Ltd has informed that Mr. JS Khorakiwala who has been on
 the board of the company as Executive Director, has resigned from the
 directorship with immediate effect.
 
 2004
 
 -Wockhardt Ltd has filed an Investigational New Drug (IND)
 application for its new drug for respiratory infections, WCK-1152
 
 - Wockhardt Ltd has acquired German pharmaceutical company esparma
 GmbH for a consideration of  million (around Rs 49 crore).
 
 -Centre for Drug Evaluation & Research, an arm of the US Food & Drug
 Administration (US FDA), has approved the sterile injectable facility
 as well as facilities for sterile bulk drugs (active pharmaceutical
 ingredient) and formulations spread over three locations in India
 
 -Wockhardt gets USFDA nod for 6 manufacturing units
 
 2005
 
 -Launches of India's first automatic insulin delivery device
 specially designed for the convenience of Indian diabetic patients on
 February 14, 2005
 
 -Wockhardt forges alliance with Kamineni Group to establish two
 world-class heart hospitals in the Hyderabad
 
 -Wockhardt unveils father`s heart network
 
 -Wockhardt receives US FDA approval for marketing cefuroxime axetil
 in the US market
 
 -Wockhardt unveils new generation hepatitis A vaccine
 
 -Wockhardt rolls out new Hepatitis A vaccine
 
 2006
 
 -Wockhardt's Waluj plant approved by US FDA
 
 2007
 
 -Wockhardt signs in-licensing pact with Crawford Healthcare of UK.
 
 -Wockhardt Ltd has appointed Mr. Rajiv B Gandhi as Director- Finance
 & Information for a period of five years effective from February 22,
 2007, subject to the approval of shareholders.
 
 -Wockhardt Ltd has announced US FDA approval for marketing Ketorolac
 anti-inflammatory injection in the US market, its third US FDA
 approval in the last ten days.
 
 
 - Wockhardt Ltd on May 03, 2007 has announced the acquisition of
 Negma Laboratories, the fourth largest independent, integrated
 pharmaceutical group in France with sales of $ 150 million. The
 Company has acquired Negma Laboratories in an all-cash deal worth $
 265 million. The transaction is valued at 1.8 times the sales and 9.7
 times the EBITDA.